RecruitingNot ApplicableNCT05093881
Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study
Sponsor
Pharmicell Co., Ltd.
Enrollment
100 participants
Start Date
Aug 24, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.
Eligibility
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called Cellgram-LC for people with alcoholic cirrhosis. The study is currently recruiting participants at 11 locations.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALCellgram-LC
Patients who had administered Cellgram-LC in PMC-P-07 study
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05093881
Related Trials
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
NCT041065189 locations
SAMe Trial for Patients With Alcoholic Cirrhosis
NCT042502592 locations
Optimized Remission in Alcohol-related Liver Cirrhosis
NCT068664961 location
Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis
NCT0468915211 locations